The glutathione-activated thiopurine prodrugs trans-6-(2-acetylvinylthio) guanine and cis-6-(2-acetylvinylthio)purine cause less in vivo toxicity than 6-thioguanine after single- and multiple-dose regimens

Molecular Cancer Therapeutics

Volumn 1, Issue 13, 2002, Pages 1211-1220

  Gunnarsdottir, Sjofn ^a   Rucki, Marian ^a   Phillips, Lynette A ^a   Young, Karen M ^a   Elfarra, Adnan A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 (2 ACETYLVINYLTHIO)GUANINE; 6-(2-ACETYLVINYLTHIO)GUANINE; 6-THIOGUANYLIC ACID; ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; DRUG DERIVATIVE; GLUTATHIONE; GUANINE; GUANINE NUCLEOTIDE; NUCLEOTIDE; PRODRUG; THIOGUANOSINE PHOSPHATE;

ANIMAL; APOPTOSIS; ARTICLE; BLOOD; BONE MARROW CELL; CELL CULTURE; COMPARATIVE STUDY; DRUG EFFECT; ERYTHROCYTE COUNT; INTESTINE MUCOSA; KIDNEY; LEUKOCYTE COUNT; LIVER; MALE; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; THROMBOCYTE COUNT;

ALANINE TRANSAMINASE; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ASPARTATE AMINOTRANSFERASES; BONE MARROW CELLS; ERYTHROCYTE COUNT; GLUTATHIONE; GUANINE; GUANINE NUCLEOTIDES; INTESTINAL MUCOSA; KIDNEY; LEUKOCYTE COUNT; LIVER; MALE; MICE; MICE, NUDE; PLATELET COUNT; PRODRUGS; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 0038474099     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Clarke, D. A., Elion, G. B., Hitchings, G. H., and Stock, C. C. Structure-activity relationships among purines related to 6-mercaptopurine. Cancer Res., 18: 445-456, 1958.
2. Martin, D. S. Purine and pyrimidine biochemistry, and some relevant clinical and preclinical cancer chemotherapy research. In: G. Powis and R. A. Prough (eds.), Metabolism and Action of Anti-Cancer Drug, pp. 91-140. New York: Taylor and Francis, 1987.
3. van Scoik, K. G., Johnson, C. A., and Porter, W. R. The pharmacology and metabolism of the thiopurine drugs 6-mercaptopurine and azathioprine. Drug Metab. Rev., 16: 157-174, 1985. (Pubitemid 16191932)
4. Krynetski, E. Y., Krynetskaia, N. F., Yanishevski, Y., and Evans, W. E. Methylation of mercaptopurine, thioguanine and their nucleotide metabolites by heterologously expressed human thiopurine S-methyltransferase. Mol. Pharmacol., 47: 1141-1147, 1995.
5. Lennard, L. The clinical pharmacology of 6-mercaptopurine. Eur. J. Clin. Pharmacol., 43: 329-339, 1992.
6. Sarcione, E. J., and Stutzman, L. A comparison of the metabolism of 6-mercaptopurine and its 6-methyl analog in the rat. Cancer Res., 20: 387-392, 1960.
7. Elion, G. B. The purine path to chemotherapy. Science (Wash. DC), 244: 41-47, 1989. (Pubitemid 19130741)
8. Adamson, P. C., Poplack, D. G., and Balis, F. M. The cytotoxicity of thioguanine versus mercaptopurine in acute lymphoblastic leukemia. Leuk. Res., 18: 805-810, 1994. (Pubitemid 24338172)
9. Dorr, R. T., and Von Hoff, D. D. Cancer Chemotherapy Handbook, 2nd ed. Norwalk, CT: Appleton & Lange, 1994.
10. Hymen, C. B., Brubaker, C., and Sturgeon, P. 6-Mercaptopurine in childhood leukemia. Comparison of large dose interrupted with small dose continuous therapy. Cancer Res., 17: 851-856, 1957.
11. Regelson, W., Holland, J. F., Frei, E., III, Gold, G. L., Hall, T., Krant, M., and Miller, S. O. Comparative clinical toxicity of 6-mercaptopurine (NSC-755) and 6-mercaptopurine ribonucleoside (NSC-4911) administered intravenously to patients with advanced cancer. Cancer Chemother. Rep., 36: 41-48, 1964.
12. Einhorn, M., and Davidshon, I. Hepatotoxicity of mercaptopurine. J. Am. Med. Assoc., 188: 802-806, 1964.
13. Horton, J., Mittelman, A., Taylor, S. G., III, Jurkowitz, L., Bennett, J. M., Ezdinli, E., Colsky, J., and Hanley, J. A. Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-thioguanine (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother. Rep., 59: 333-340, 1975.
14. Moore, G. E., Bross, I. D. J., Ausman, R., Nadler, S., Jones, R., Jr., Slack, N., and Rimm, A. A. Effects of 6-mercaptopurine (NSC-755) in 290 patients with advanced cancer. Cancer Chemother. Rep., 52: 655-660, 1968.
15. Frank, W., and Tornyos, K. The effectiveness of 2-amino-6-[(1-methyl-4- nitro-5-imidazolyl)thio]purine (B.W. 57-323) in metastatic squamous cell carcinoma of the oropharynx and larynx. Cancer Chemother. Rep., 20: 113-115, 1962.
16. 6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug resistance in tumor and normal lung of patients with lung cancer. Int. J. Cancer, 59: 629-636, 1994.
17. Mekhail-Ishak, K., Hudson, N., Tsao, M-S., and Batist, G. Implications for therapy of drug-metabolizing enzymes in human colon cancer. Cancer Res., 49: 4866-4869, 1989. (Pubitemid 19213639)
18. Buser, K., Joncourt, F., Altermatt, H-J., Bacchi, M., Oberli, A., and Cerny, T. Breast cancer: pretreament drug resistance parameters (GSH-system, ATase, P-glycoprotein) in tumor tissue and their correlation with clinical and prognostic characteristics. Ann. Oncol., 8: 335-341, 1997. (Pubitemid 27230973)
19. Schröder, C. P., Godwin, A. K., O'Dwyer, P. J., Tew, K. D., Hamilton, T. C., and Ozols, R. F. Glutathione and drug resistance. Cancer Investig., 14: 158-168, 1996. (Pubitemid 26109331)
20. Davis, W., Ronai, Z., and Tew, K. D. Cellular thiols and reactive oxygen species in drug-induced apoptosis. J. Pharmacol. Exp. Ther., 296: 1-6, 2001. (Pubitemid 32015053)
21. Coppola, S., and Ghibelli, L. GSH extrusion and the mitochondrial pathway of apoptotic signalling. Biochem. Soc. Trans., 28: 56-61, 2000. (Pubitemid 30103213)
22. Hall, A. G. The role of glutathione in the regulation of apoptosis. Eur. J. Clin. Investig., 29: 238-245, 1999. (Pubitemid 29106315)
23. Joncourt, F., Buser, K., Altermatt, H., Bacchi, M., Oberli, A., and Cerny, T. Multiple drug resistance parameter expression in ovarian cancer. Gynecol. Oncol., 70: 176-182, 1998. (Pubitemid 28430925)
24. Perry, R. R., Mazetta, J., Levin, M., and Barranco, S. C. Glutathione levels and variability in breast tumor and normal tissue. Cancer (Phila.), 72: 786-787, 1993.
25. Mickisch, G., Bier, H., Bergler, W., Bak, M., Tschada, R., and Alken, P. P-170 glycoprotein, glutathione and associated enzymes in relation to chemoresistance of primary human renal cell carcinomas. Urol. Int., 45: 170-176, 1990. (Pubitemid 20172046)
26. O'Brien, M. L., and Tew, K. D. Glutathione and related enzymes in multidrug resistance. Eur. J. Cancer, 32A: 967-978, 1996.
27. Barranco, S. C., Perry, R. R., Durm, M. E., Quraishi, M., Werner, A. L., Gregorcyk, A. G., and Kolm, P. Relationship between colorectal cancer glutathione levels and patient survival: early results. Dis. Colon Rectum, 43: 1133-1140, 2000. (Pubitemid 30626147)
28. Gunnarsdottir, S., Rucki, M., and Elfarra, A. A. Novel glutathionedependent thiopurine prodrugs: evidence for enhanced cytotoxicity in tumor cells and for decreased bone marrow toxicity in mice. J. Pharmacol. Exp. Ther., 301: 77-86, 2002. (Pubitemid 34250282)
29. Gunnarsdottir, S., Rucki, M., Phillips, L. A., Young, K. M., and Elfarra, A. A. Novel glutathione-activated thiopurine prodrugs exhibit less bone marrow and intestinal toxicity than 6-thioguanine. Proc. Am. Assoc. Cancer Res., 43: 79, 2002.
30. Bergmann, F., and Ungar, H. The enzymatic oxidation of 6-mercaptopurine to 6-thiouric acid. J. Am. Chem. Soc., 82: 3957-3960, 1960.
31. Latta, J. S., and Gentry, R. P. The hematological alterations resulting from repeated injections of 6-mercaptopurine into AKR mice. Anat. Rec., 132: 1-23, 1958.
32. Philips, S. F., Sternberg, S. S., Hamilton, L. D., and Clarke, D. A. The toxic effects of 6-mercaptopurine and related compounds. Ann. N. Y. Acad. Sci., 60: 283-296, 1954.
33. Philips, S. F., Sternberg, S. S., Hamilton, L. D., and Clarke, D. A. Effects of thioguanine in mammals. Cancer (Phila.), 9: 1092-1101, 1956.
34. Clarke, D. A., Philips, F. S., Sternberg, S. S., Stock, C. C., Elion, G. B., and Hitchings, G. H. 6-Mercaptopurine: effects in mouse sarcoma 180 and in normal animals. Cancer Res., 13: 593-604, 1953.
35. Nelson, J. A., and Vidale, E. Formation of 6-thioguanine and 6-mercaptopurine from their 9-alkyl derivatives in mice. Cancer Res., 46: 137-140, 1986. (Pubitemid 16189042)
36. Hollingsworth, J. W. Inhibition by cytotoxic drugs of bone marrow regeneration after irradiation and marrow transplantation. Cancer Res., 19: 165-169, 1959.
37. Elion, G. B., Bieber, S., and Hitchings, G. H. A summary of investigations with 2-amino-6-[(1-methyl-4-nitro-5-imidazolyl)thio]purine (B.W. 57-323) in animals. Cancer Chemother. Rep., 8: 36-43, 1960.
38. Elion, G. B., Callahan, S., Bieber, S., Hitchings, G. H., and Rundles, R. W. A summary of investigations with 6-[(1-methyl-4-nitro-5-imidazolyl) thio]purine (B.W. 57-322). Cancer Chemother. Rep., 14: 93-98, 1961.
39. Endresen, L., Lie, S. O., Storm-Mathisen, I., Rugstad, H. E., and Stokke, O. Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug. Ther. Drug Monit., 12: 227-234, 1990. (Pubitemid 20150886)
40. Erb, N., Harms, D. O., and Janka-Schaub, G. Pharmacokinetics and metabolism of thiopurines in children with acute lymphoplastic leukemia given 6-thioguanine versus 6-mercaptopurine. Cancer Chemother. Pharmacol., 42: 266-272, 1998. (Pubitemid 28393842)